Curaleaf Worldwide, a part of Curaleaf Holdings (TSX:CURA) and considered one of Europe’s largest vertically built-in hashish corporations, is increasing into the Czech Republic, a brand new marketplace for the corporate, via a brand new provide settlement with Astrasana Pharma s.r.o.
The Czech Republic, broadly considered one of the crucial progressive nations in Europe, legalised medical hashish in 2013. Extra not too long ago the market has skilled important development, and projections counsel that the market is ready to triple by 2027, demonstrating the potential of the business throughout the nation.
The partnership with Astrasana Pharma s.r.o will see Curaleaf Worldwide’s EU-GMP flower made accessible to sufferers through Pilulka Pharmacy, a number one healthcare supplier within the area. This collaboration underscores Curaleaf Worldwide’s dedication to offering sufferers with dependable entry to medical hashish merchandise whereas sustaining the very best requirements of high quality and repair.
Juan Pablo Martinez, Head of Curaleaf Worldwide mentioned, “Our partnership with Astrasana Pharma s.r.o. signifies one other step ahead within the rising European medical hashish market. By working collectively, we purpose to boost entry to high-quality medical hashish within the Czech Republic.
“Amidst growing demand for medical hashish in Europe, this collaboration highlights our dedication to offering dependable merchandise and driving progress in healthcare. Collectively, we’re facilitating affected person entry and contributing to the evolution of the medicinal hashish business.”
